Literature DB >> 22736731

Positron emission tomography with computed tomography (PET-CT) to evaluate the response of bone metastases to non-surgical treatment.

Peter Denzil Correa1, Raj Kumar Shrimali, Sai Han, Mohammed Rizwanullah.   

Abstract

A case of solitary bone metastasis from breast cancer, where MRI assessment of treatment response was inaccurate and whole-body fluorodeoxyglucose ((18)FDG) positron emission tomography with computed tomography (PET-CT) proved more reliable and objective, is presented.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 22736731      PMCID： PMC3047492          DOI： 10.1136/bcr.11.2009.2457

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


  3 in total

1.  Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP).

Authors:  Jennifer M Specht; Stephen L Tam; Brenda F Kurland; Julie R Gralow; Robert B Livingston; Hannah M Linden; Georgiana K Ellis; Erin K Schubert; Lisa K Dunnwald; David A Mankoff
Journal:  Breast Cancer Res Treat       Date:  2007-02-01       Impact factor: 4.872

Review 2.  Bone imaging in metastatic breast cancer.

Authors:  Tsuyoshi Hamaoka; John E Madewell; Donald A Podoloff; Gabriel N Hortobagyi; Naoto T Ueno
Journal:  J Clin Oncol       Date:  2004-07-15       Impact factor: 44.544

3.  Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy.

Authors:  Stephanie E Stafford; Julie R Gralow; Erin K Schubert; Kristine J Rinn; Lisa K Dunnwald; Robert B Livingston; David A Mankoff
Journal:  Acad Radiol       Date:  2002-08       Impact factor: 3.173
  3 in total
  1 in total

1.  Magnetic resonance-guided focused ultrasound for the treatment of painful bone metastases: role of apparent diffusion coefficient (ADC) and dynamic contrast enhanced (DCE) MRI in the assessment of clinical outcome.

Authors:  Michele Anzidei; Alessandro Napoli; Beatrice Sacconi; Fabrizio Boni; Vincenzo Noce; Michele Di Martino; Luca Saba; Carlo Catalano
Journal:  Radiol Med       Date:  2016-08-27       Impact factor: 3.469
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.